Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged...

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• ALK-rearranged non-small cell lung cancer (NSCLC) survival has improved with ALK-tyrosine kinase inhibitors (TKIs).
• Real-world data on the impact of drug sequencing and clinical factors on survival in ALK-rearranged NSCLC is limited.

Observation:

• A study included 121 patients with stage IV ALK-rearranged NSCLC diagnosed between 2011 and 2016.
• Median overall survival (OS) from diagnosis of stage IV disease was 48.0 months.
• First-line treatment included an ALK-TKI in 24% of patients, primarily crizotinib.

Findings:

• The use of multiple ALK-TKI lines positively correlated with improved OS (p=0.016).
• Alectinib or lorlatinib use in any line improved OS compared to crizotinib ± ceritinib (p=0.022).
• Never smoking history was an independent prognostic factor for OS (p=0.032), and alectinib treatment significantly improved OS.

Implications:

• Targeted therapies, particularly sequential ALK-TKIs like alectinib and lorlatinib, prolong OS in ALK-positive NSCLC.
• Smoking status is a crucial independent prognostic factor in multivariate analysis for ALK-rearranged NSCLC.
• Real-world evidence supports the efficacy of specific ALK-TKIs and highlights the importance of patient characteristics in treatment outcomes.